The ethicist's view Dr Richard Nicholson (Editor, Bulletin of Medical Ethics) started with the assertion that ethical review of clinical research in the United Kingdom is unsatisfactory. He pointed out that the Institutional Review Boards (IRBs) in the USA have a statutory basis but there is no such foundation for ethics committees in the UK. He cited a review of the ethics of clinical research in children which was carried out in 1983 by the Institute of Medical Ethics. Questionnaires were sent to 254 research ethics committees in the UK of which 174 (69%)responded. The committees ranged in size from 3 to 41 members and 118 of the 174 committees (68%) had no paediatrician as a member; 76 committees (44%)had no general practitioner, 86 (49%) no nurse and 14 (8%)no lay member. In conducting their business, 19 (11%)of the committees never met, communicating only by post and telephone. The time taken to reach a decision was, in many cases, unhelpful to clinical investigators with 30% taking 7 weeks, or more. The Chairmen of 36% of the committees were uncertain of the source from which the committee derived its authority. These results indicated a general unsatisfactory state of affairs which had not noticeably improved in the intervening 7 years if notice was to be taken of some recent evidence in medical journals.
Dr Nicholson cited a recent letter in the Lancets describing a study carried out in children in which the design was open to criticism and no mention was made of the protocol having been submitted to ethical review. Moreover, in a four-page article on how to organize a multicentre clinical trial, no mention was made of review of the study by an ethics committee''. This gives the impression that ethics are not an integral part of the research process. In an important editorial on ethics committees in the British Medical Journals, Dr Stephen Lock reminded readers of the differences between practices in the USA and the UK and called for standardization of practice in this country and monitoring of the workings of local ethics committees. The medical profession needs to act before it becomes too late and regulation is imposed upon it from outside.
Dr Nicholson seemed to be in favour of it becoming a contractual requirement for all employees in the National Health Service to submit their research proposals to an ethics committee. Insurance cover should be invalid if the approval of a properly constituted ethics committee had not been obtained for any clinical research. He also stated that ethics committees should be required to produce annual reports which are available for public scrutiny and analysis.
The neglect of medical ethics in the UK is illustrated by the paucity of attention paid to it in medical schools, the absence of centres for medical ethics and the lack of funding for the teaching and research of medical ethics in the UK: there is greater expenditure on medical ethics in one centre in Oslo than there is in the whole of the UK. These matters are important because if the medical profession does not assume responsibility for ethics, the government is likely, under public pressure, to take over issues that are essentially of ethical concern. The medical profession must take the needs and the rights of patients much more seriously than they do at present. At present, the Community Health Councils are the only means whereby patients' interests are represented in the National Health Service but the establishment of pressure groups, such as Consumers for Ethics and Research (CERES), indicates the concern and the possible direction of developments.
The lawyer's view After the ethicist, Mrs Diana Brahams (medico-legal correspondent, Lancet) introduced a legal flavour to ethics based upon her 9 years' experience of writing the 'Medicines and the Law' column in the Lancet. In 19824, she had reported and commented on the inquest of an 84-year-oldwidow who had died and who had been the unwitting subject of a randomized controlled trial of 5-fluorouracil given into the portal vein. This was the first medico-legal case with an ethical problem that she had encountered; until this time she had naively thought that ethics were an integral part of medical teaching. Just two years later, at the inquest on a 69-year-old woman who had died in a coma while participating in a clinical trial of an analgesic for the relief of postoperative pain, it had been revealed that the patient had been reluctant to take part in the trial and her husband had also been opposed to it 5 • However, pressure from her daughter, after discussions with, and reassurance by, the nursing staff, had apparently persuaded the woman to agree to entry to the study on the basis that patients in formal clinical trials were likely to receive 'better treatment'. In Mrs Brahams' view, since these cases in the early 1980s, and following the adverse publicity that they generated, there has been a marked change in attitudes to information and consent for patients undergoing medical treatment in clinical trials. Cancer patients now seem to be better informed than formerly (although a report in the Independent newspaper on the 23 January 1990 indicates that there is still much room for improvement).
A large proportion of medico-legal litigation is concerned with issues of informed consent although, in the UK, the patient's right to information is somewhat limited. Contrary to popular opinion, the legal profession gives only general, or outline, guidance and leaves it to the medical profession to The general principles are that patients should know what is involved with any medical or surgical procedure and should be told the real risks. English law does not require that patients are told all the available options. In patients with cancer the options for treatment vary, often involving difficult choices, and doctors can limit themselves to describing what they consider to be the best of the alternatives. There is a danger that double standards will evolve with limited information and discussion in normal clinical practice and a much more extensive exercise of informed consent in formal clinical research?
It should be remembered that the aim of getting the consent of an ethics committee for experimental procedures is to ensure that patients' interests are protected. It should not be viewed as a purely procedural and defensive step in the trial process.
The surgeon's view Finally came the views of the practising and experienced researcher, Professor Michael Baum (Kings College Hospital, London) who had been the subject of quite strong criticism in a 'quality' Sunday newspaper in October 1988. Professor Baum reminded the audience that therapeutic decisions in clinical research were no different from those in clinical medicine. The doctor/patient relationship is an important condition for establishing a patient's wishes; some patients may not wish to express their autonomy in the decision-making process. The doctor's approach differs from that of the patient in that quality of evidence is probably the most important determining factor in coming to a decision. There is a hierarchy of the strength and quality of evidence ranging from the comparative weakness of the anecdotal case report to the strength of the multiple clinical trial evaluated by metaanalysis.
He agreed with Mrs Brahams over the issue of double standards, quoting the example of treatment for breast cancer as an example. The alternatives are mastectomy or lumpectomy and there is no strong evidence to favour either procedure. It is common to find that some surgeons perform one, or the other, operation routinely without informing their patients of the alternative while yet others vary their procedure from patient to patient; a few may leave the choice to the patient. An attempt to perform a properly conducted scientific study which took 3 years to be passed by an ethics committee was abandoned after a further 3 years so leaving the optimum treatment undecided. The double standards were well illustrated by the fact that patients were given a free choice whether they would like to enter the study but it was only those who chose to do so who were guaranteed fully-informed consent.
The Declaration of Helsinki which covers human experimentation requires that each potential subject must be adequately informed of the aims, methods, expected benefits and potential hazards of the proposed study but there is a measure of internal contradiction in the subsequent qualifying clauses which specify exclusions and state qualifications.
Professor Baum asked what is the purpose of informed consent? Is it to protect the patient from unethical practices, or the doctor from litigation? The principal motives of almost all clinical researchers are entirely creditable but Professor Baum acknowledged that the public and patients needed the protection of ethical restraints. In planning research, the bodies which provided the funds required reassurance that both the ethics and the science of the proposed research were punctilious. However, Leon Eisenberg had pointed out that there were ethical consequences in impeding, as well as in doing, medical research.
Professor Baum thought that non-therapeutic research, that is, what are generally known as Phases I and II of clinical trials, should be the subject of fully informed consent and of review by local ethics committees. Major, national controlled trials (Phase Ill) should be reviewed by a national ethics committee, subject to a publicity campaign to inform the public, and be covered by a standard consent form indicating that adequate information had been properly conveyed to, and understood by, the patient.
Discussion
During the discussion which followed it was pointed out that, in a clinical trial, the doctor/patient relationship changes. In a research study, the treatments that patients receive have been chosen not because they are the best for the individuals, but to determine which is the best for the community. There is a potential clash of values which doctors must get right. In clinical trials, patients should not have their consultations and care delegated to other people but should be under the direct supervision of the clinical researcher throughout. All ethics committees should be given reports of the studies which they had passed.
Summary
The meeting was convened to provide a forum for the discussion of those aspects of medical ethics which concerned clinical research, particularly the clinical studies which the pharmaceutical industry is required to carry out to satisfy regulatory authorities for them to issue licences for the introduction of new medicines. While the speakers did not confine themselves to this topic, they did raise many issues which impinge on clinical research with medicines. It is unfortunate that the meeting coincided with a severe storm which undoubtedly restricted the audience and, therefore, the discussion which was intended. However, those who attended were fortunate to hear three excellent speakers give their personal views on an important subject which tends to be the Cinderella topic among clinical researchers and the pharmaceutical industry. However, all three speakers made the audience aware of the significance of ethics in all research on humans and the need for more education of both the profession and the public on this subject. . He eschewed a detailed description of the physics of MRI but gave a lucid explanation of the principles of magnetic resonance. Protons placed in a strong magnetic field align with each other and their axis of spin is tilted and rotated. When a radiofrequency (RF) pulse is applied at 90°to the field this causes the protons to change their vector of rotation. This is called resonance. Following the RF pulse and resonance absorption the protons relax back to their previous state emitting characteristic RF waves. This energy is measured and used to construct an image. The emitted RF pulse intensity or signal is proportional, amongst other things, to the proton density. Hydrogen nuclei can be considered to be single protons and act like small bar magnets. As the human body consists largely of water and fat with hydrogen bound in both it is this hydrogen that is imaged by MRI. The length of time taken for decay of signal when the RF generator is switched off is known as the relaxation time. There are two main relaxation factors Tl and T2. Tl is a measure of the time taken for the longitudinal magnetization to return to equilibrium and represents relaxation between the spinning proton and the environment (spin/lattice). The T2 relaxation time is a measure of the transverse relaxation between different protons (spin/spin). Although both factors operate in all three planes Tl is predominantly longitudinal and T2 transverse. Tl values of biological tissues are generally longer than T2. The measurement of the initial size of the signal and its relaxation times by MRI gives a physical profile of tissue constituents. The application of different RF pulse sequences produces signals weighted to proton density or different degrees of Tl and T2 relaxation times. The simplest sequence is known as saturation recovery in which there is a single 90°p ulse and a long repetition time between pulses. The image produced by signal measurement immediately after the pulse depends on proton density. Rapid repetition of the sequence allows only partial relaxation and results depend on both proton density and Tl (partial saturation recovery). In practice, most centres use Spin Echo (SE)techniques where an initial 90°pulse is followed by a 180°pulse. By altering the repetition time (TR) and time to echo (TE), either a Tl, T2 or proton density (balanced) image can be produced. Another technique is the Inversion Recovery (IR)sequence in which an initial 180°pulse is followed by a 90°pulse. The STIR sequence is a variant of the Inversion Recovery in which the time to inversion (TI or Tau) is short (Short Tau Inversion Recovery). This sequence suppresses fat and summates T1 and T2. By altering the pulse sequences and hence the weighting towards the various magnetic properties the signal emanating from various structures can be completely altered. Fat, which usually gives a high signal, can be suppressed using the STIR sequence. Urine may appear of low density (black) on one sequence but high (white) on another. This well illustrated address by Dr Dixon allowed the attending members and guests of both sections to understand not only the principles of MRI but its enormous potential. Its advantages of excellent tissue differentiation, multiplanar imaging and lack of ionizing radiation were readily appreciated. The limitations of high cost, time consuming investigation (average 1 h), and claustrophobia in a few patients (1-5%) have to be considered.
Peter J Keen

Editorial Representatiue Library (Scientific Research) Section
The practical application of magnetic resonance imaging in urological disease was considered by Mr J C Gingell (Consultant Urologist, Southmead Hospital, Bristol). He intimated that the role ofMRI scanning was now well established in the CNS, spine and musculoskeletal systems. Its application in imaging the CVS, gastrointestinal tract and pelvis was progressing but that its role in urology was as yet undecided.
In Bristol a Picker Vista 0.5 Tesla superconducting MRI scanner was purchased by a gift of one million pounds from Mr John James CBE, LLD. The NHS was unable to fund the building and the money to house the machine was raised by public appeal launched by the trustees. Patient examination began in early June 1987 and 1600 patients were examined in the first year. The experience to date in the imaging of the urinary tract was presented and an attempt made to evaluate the role of MRI in urological disease.
Prostate gland
The 'gold standard' for imaging the prostate gland is transrectal ultrasonography. With modem probes the prostate can be imaged in both the coronal and sagittal planes thereby making volumetric assessment reasonably accurately. Apart from assessing prostatic size it is important to differentiate benign hyper. trophy from carcinoma. In addition to recognizing carcinoma of the prostate the clinical stage of the disease or degree of local invasion must be assessed. One therefore needs to identify the capsule of the prostate and the seminal vesicles. In our experience 
